Plant Compound Cycloastragenol Shows Promise Against Alzheimer's Disease

Alzheimer's disease affects millions worldwide, with limited treatment options targeting the underlying disease mechanisms. This study explores cycloastragenol (CAG), a natural compound from Astragalus plants known for anti-aging and anti-inflammatory properties, as a potential Alzheimer's therapy.

Researchers used 5×FAD mice, a well-established Alzheimer's model, to test CAG's effects. They employed cutting-edge techniques including single-cell RNA sequencing, network pharmacology, and molecular docking to identify how CAG works at the cellular level.

Key results showed CAG significantly improved cognitive function and reduced brain pathology. Most importantly, it enhanced microglia—the brain's resident immune cells—making them more effective at clearing toxic amyloid plaques. The compound also reduced microglial senescence, essentially rejuvenating these critical brain cells.

The mechanism involves CAG binding to phosphodiesterase 4B (PDE4B), which activates the CREB/BDNF pathway. This molecular cascade restores microglial phagocytic function, enabling better clearance of disease-causing proteins while reducing neuroinflammation.

These findings suggest a paradigm shift in Alzheimer's treatment—rather than solely targeting amyloid plaques, enhancing the brain's natural cleanup mechanisms through microglial restoration could be more effective. However, this remains preclinical research requiring human trials to confirm safety and efficacy.